• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.

作者信息

Takahashi S, Okada K, Kinosita Y, Yanai M, Kuno T, Nagura Y

机构信息

Nishi-Kofu National Hospital, Yamanashi, Japan.

出版信息

Nihon Jinzo Gakkai Shi. 1993 Apr;35(4):377-82.

PMID:8341016
Abstract

We examined the effect of oral 1,25(OH)2D3 pulse therapy in hemodialyzed patients with secondary hyperparthyroidism (2 degrees HPT). Prescription of 6.0 micrograms 1,25(OH)2D3 once a week combined with calcium carbonate as a phosphate binder during the last 5 days a week for 12 weeks resulted in improvement of mild to moderate 2 degrees HPT despite no significant differences in serum total calcium and phosphate concentration. In addition, the effect was greater in cases with mild 2 degrees HPT. A single administration of 6 micrograms 1,25(OH)2D3 reduced the parathyroid hormone concentration in patients with mild 2 degrees HPT or with a short duration of hemodialysis. Tmax of the serum 1,25(OH)2D3 after single administration of 6.0 micrograms 1,25(OH)2D3 was individually different (range, 0.4-20.9 hrs). It is recommended that early employment of oral 1,25(OH)2D3 pulse therapy be undertaken once a week combined with prescription of calcium salt as a phosphate binder during the last 5 days a week for the treatment of 2 degrees HPT refractory to conventional therapy, since there is no risk of aluminum accumulation with satisfactory control of the serum total calcium and phosphate concentration.

摘要

相似文献

1
Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
Nihon Jinzo Gakkai Shi. 1993 Apr;35(4):377-82.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
[Methylguanidine kinetics during oral active vitamin D pulse therapy for secondary hyperparathyroidism].[继发性甲状旁腺功能亢进口服活性维生素D脉冲治疗期间的甲基胍动力学]
Nihon Jinzo Gakkai Shi. 1992 Feb;34(2):163-9.
4
Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.
Miner Electrolyte Metab. 1995;21(1-3):223-8.
5
[The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
Nihon Jinzo Gakkai Shi. 1992 Jul;34(7):807-11.
6
[A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Nihon Jinzo Gakkai Shi. 1989 Apr;31(4):393-401.
7
Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
Am J Nephrol. 1993;13(2):149-54. doi: 10.1159/000168606.
8
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.静脉注射1,25 - 二羟胆钙化醇对尿毒症患者继发性甲状旁腺功能亢进有显著抑制作用。
J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639.
9
The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Nephron. 1991;57(1):23-8. doi: 10.1159/000186210.
10
Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.腹膜透析患者继发性甲状旁腺功能亢进的脉冲式静脉注射骨化三醇治疗
Adv Perit Dial. 1993;9:260-3.